Harvard Bioscience (HBIO) Short-Term Debt repayments (2021 - 2025)

Harvard Bioscience (HBIO) has 5 years of Short-Term Debt repayments data on file, last reported at $12.6 million in Q4 2025.

• Quarterly Short-Term Debt repayments changed N/A year-over-year to $12.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (up 396.08% YoY) and the FY2025 annual result came in at $12.6 million, up 396.08% from the prior year.
• Short-Term Debt repayments rose to $12.6 million in Q4 2025 per HBIO's latest filing, from $2.0 million in the prior quarter.
• Across five years, Short-Term Debt repayments topped out at $12.6 million in Q4 2025 and bottomed at -$1.8 million in Q4 2021.
• The 5-year median for Short-Term Debt repayments is $2.5 million (2023), against an average of $2.9 million.
• The widest annual swing landed in 2022, when Short-Term Debt repayments jumped 197.22%; it then tumbled 80.0% in 2024.
• Tracing HBIO's Short-Term Debt repayments over 5 years: stood at -$1.8 million in 2021, then jumped by 197.22% to $1.8 million in 2022, then jumped by 42.86% to $2.5 million in 2023, then retreated by 18.0% to $2.0 million in 2024, then soared by 517.07% to $12.6 million in 2025.
• Per Business Quant, the three latest HBIO Short-Term Debt repayments figures stand at $12.6 million (Q4 2025), $2.0 million (Q2 2024), and $500000.0 (Q1 2024).

Peer Comparison